Global Human Papillomavirus Vaccine market is expected to grow from US$ 2352 million in 2025 to US$ 2793 million in 2031; it is expected to grow at a CAGR of 2.9% from 2025 to 2031.

Global Human Papillomavirus Vaccine Market Size and Outlook 2025-31

The global Human Papillomavirus Vaccine market size is predicted to grow from US$ 2352 million in 2025 to US$ 2793 million in 2031; it is expected to grow at a CAGR of 2.9% from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. Human papilloma virus (HPV) vaccine is a vaccine that prevents infection by certain types of human papillomavirus. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Human Papillomavirus Vaccine Industry Forecast looks at past sales and reviews total world Human Papillomavirus Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Papillomavirus Vaccine sales for 2025 through 2031. With Human Papillomavirus Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Papillomavirus Vaccine industry. This Insight Report provides a comprehensive analysis of the global Human Papillomavirus Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Papillomavirus Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Human Papillomavirus Vaccine market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Papillomavirus Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Papillomavirus Vaccine. This report presents a comprehensive overview, market shares, and growth opportunities of Human Papillomavirus Vaccine market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Bivalent &nbsp;&nbsp;&nbsp; Quadrivalent &nbsp;&nbsp;&nbsp; Nonavalent Segmentation by Application: &nbsp;&nbsp;&nbsp; Cervical Cancer &nbsp;&nbsp;&nbsp; Anal Cancer &nbsp;&nbsp;&nbsp; Penile Cancer &nbsp;&nbsp;&nbsp; Oropharyngeal Cancer &nbsp;&nbsp;&nbsp; Genital Warts &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; GlaxoSmithKline &nbsp;&nbsp;&nbsp; Sanofi &nbsp;&nbsp;&nbsp; Johnson & Johnson &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; Serum Institute &nbsp;&nbsp;&nbsp; Wantai Biological &nbsp;&nbsp;&nbsp; KM Biologics &nbsp;&nbsp;&nbsp; Bharat Biotech Key Questions Addressed in this Report What is the 10-year outlook for the global Human Papillomavirus Vaccine market? What factors are driving Human Papillomavirus Vaccine market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Human Papillomavirus Vaccine market opportunities vary by end market size? How does Human Papillomavirus Vaccine break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Human Papillomavirus Vaccine Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Human Papillomavirus Vaccine by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Human Papillomavirus Vaccine by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Human Papillomavirus Vaccine Segment by Type &nbsp;2.2.1 Bivalent &nbsp;2.2.2 Quadrivalent &nbsp;2.2.3 Nonavalent &nbsp;2.3 Human Papillomavirus Vaccine Sales by Type &nbsp;2.3.1 Global Human Papillomavirus Vaccine Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Human Papillomavirus Vaccine Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Human Papillomavirus Vaccine Sale Price by Type (2020-2025) &nbsp;2.4 Human Papillomavirus Vaccine Segment by Application &nbsp;2.4.1 Cervical Cancer &nbsp;2.4.2 Anal Cancer &nbsp;2.4.3 Penile Cancer &nbsp;2.4.4 Oropharyngeal Cancer &nbsp;2.4.5 Genital Warts &nbsp;2.4.6 Others &nbsp;2.5 Human Papillomavirus Vaccine Sales by Application &nbsp;2.5.1 Global Human Papillomavirus Vaccine Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Human Papillomavirus Vaccine Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Human Papillomavirus Vaccine Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Human Papillomavirus Vaccine Breakdown Data by Company &nbsp;3.1.1 Global Human Papillomavirus Vaccine Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Human Papillomavirus Vaccine Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Human Papillomavirus Vaccine Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Human Papillomavirus Vaccine Revenue by Company (2020-2025) &nbsp;3.2.2 Global Human Papillomavirus Vaccine Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Human Papillomavirus Vaccine Sale Price by Company &nbsp;3.4 Key Manufacturers Human Papillomavirus Vaccine Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Human Papillomavirus Vaccine Product Location Distribution &nbsp;3.4.2 Players Human Papillomavirus Vaccine Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Human Papillomavirus Vaccine by Geographic Region &nbsp;4.1 World Historic Human Papillomavirus Vaccine Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Human Papillomavirus Vaccine Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Human Papillomavirus Vaccine Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Human Papillomavirus Vaccine Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Human Papillomavirus Vaccine Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Human Papillomavirus Vaccine Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Human Papillomavirus Vaccine Sales Growth &nbsp;4.4 APAC Human Papillomavirus Vaccine Sales Growth &nbsp;4.5 Europe Human Papillomavirus Vaccine Sales Growth &nbsp;4.6 Middle East & Africa Human Papillomavirus Vaccine Sales Growth 5 Americas &nbsp;5.1 Americas Human Papillomavirus Vaccine Sales by Country &nbsp;5.1.1 Americas Human Papillomavirus Vaccine Sales by Country (2020-2025) &nbsp;5.1.2 Americas Human Papillomavirus Vaccine Revenue by Country (2020-2025) &nbsp;5.2 Americas Human Papillomavirus Vaccine Sales by Type (2020-2025) &nbsp;5.3 Americas Human Papillomavirus Vaccine Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Human Papillomavirus Vaccine Sales by Region &nbsp;6.1.1 APAC Human Papillomavirus Vaccine Sales by Region (2020-2025) &nbsp;6.1.2 APAC Human Papillomavirus Vaccine Revenue by Region (2020-2025) &nbsp;6.2 APAC Human Papillomavirus Vaccine Sales by Type (2020-2025) &nbsp;6.3 APAC Human Papillomavirus Vaccine Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Human Papillomavirus Vaccine by Country &nbsp;7.1.1 Europe Human Papillomavirus Vaccine Sales by Country (2020-2025) &nbsp;7.1.2 Europe Human Papillomavirus Vaccine Revenue by Country (2020-2025) &nbsp;7.2 Europe Human Papillomavirus Vaccine Sales by Type (2020-2025) &nbsp;7.3 Europe Human Papillomavirus Vaccine Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Human Papillomavirus Vaccine by Country &nbsp;8.1.1 Middle East & Africa Human Papillomavirus Vaccine Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Human Papillomavirus Vaccine Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Human Papillomavirus Vaccine Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Human Papillomavirus Vaccine Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Human Papillomavirus Vaccine &nbsp;10.3 Manufacturing Process Analysis of Human Papillomavirus Vaccine &nbsp;10.4 Industry Chain Structure of Human Papillomavirus Vaccine 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Human Papillomavirus Vaccine Distributors &nbsp;11.3 Human Papillomavirus Vaccine Customer 12 World Forecast Review for Human Papillomavirus Vaccine by Geographic Region &nbsp;12.1 Global Human Papillomavirus Vaccine Market Size Forecast by Region &nbsp;12.1.1 Global Human Papillomavirus Vaccine Forecast by Region (2026-2031) &nbsp;12.1.2 Global Human Papillomavirus Vaccine Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Human Papillomavirus Vaccine Forecast by Type (2026-2031) &nbsp;12.7 Global Human Papillomavirus Vaccine Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Merck &nbsp;13.1.1 Merck Company Information &nbsp;13.1.2 Merck Human Papillomavirus Vaccine Product Portfolios and Specifications &nbsp;13.1.3 Merck Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Merck Main Business Overview &nbsp;13.1.5 Merck Latest Developments &nbsp;13.2 GlaxoSmithKline &nbsp;13.2.1 GlaxoSmithKline Company Information &nbsp;13.2.2 GlaxoSmithKline Human Papillomavirus Vaccine Product Portfolios and Specifications &nbsp;13.2.3 GlaxoSmithKline Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 GlaxoSmithKline Main Business Overview &nbsp;13.2.5 GlaxoSmithKline Latest Developments &nbsp;13.3 Sanofi &nbsp;13.3.1 Sanofi Company Information &nbsp;13.3.2 Sanofi Human Papillomavirus Vaccine Product Portfolios and Specifications &nbsp;13.3.3 Sanofi Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Sanofi Main Business Overview &nbsp;13.3.5 Sanofi Latest Developments &nbsp;13.4 Johnson & Johnson &nbsp;13.4.1 Johnson & Johnson Company Information &nbsp;13.4.2 Johnson & Johnson Human Papillomavirus Vaccine Product Portfolios and Specifications &nbsp;13.4.3 Johnson & Johnson Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Johnson & Johnson Main Business Overview &nbsp;13.4.5 Johnson & Johnson Latest Developments &nbsp;13.5 AstraZeneca &nbsp;13.5.1 AstraZeneca Company Information &nbsp;13.5.2 AstraZeneca Human Papillomavirus Vaccine Product Portfolios and Specifications &nbsp;13.5.3 AstraZeneca Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 AstraZeneca Main Business Overview &nbsp;13.5.5 AstraZeneca Latest Developments &nbsp;13.6 Serum Institute &nbsp;13.6.1 Serum Institute Company Information &nbsp;13.6.2 Serum Institute Human Papillomavirus Vaccine Product Portfolios and Specifications &nbsp;13.6.3 Serum Institute Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Serum Institute Main Business Overview &nbsp;13.6.5 Serum Institute Latest Developments &nbsp;13.7 Wantai Biological &nbsp;13.7.1 Wantai Biological Company Information &nbsp;13.7.2 Wantai Biological Human Papillomavirus Vaccine Product Portfolios and Specifications &nbsp;13.7.3 Wantai Biological Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Wantai Biological Main Business Overview &nbsp;13.7.5 Wantai Biological Latest Developments &nbsp;13.8 KM Biologics &nbsp;13.8.1 KM Biologics Company Information &nbsp;13.8.2 KM Biologics Human Papillomavirus Vaccine Product Portfolios and Specifications &nbsp;13.8.3 KM Biologics Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 KM Biologics Main Business Overview &nbsp;13.8.5 KM Biologics Latest Developments &nbsp;13.9 Bharat Biotech &nbsp;13.9.1 Bharat Biotech Company Information &nbsp;13.9.2 Bharat Biotech Human Papillomavirus Vaccine Product Portfolios and Specifications &nbsp;13.9.3 Bharat Biotech Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Bharat Biotech Main Business Overview &nbsp;13.9.5 Bharat Biotech Latest Developments 14 Research Findings and Conclusion

Report	Global Human Papillomavirus Vaccine Market Growth 2025-2031
Selected License	Multi ID: LPI24658

Buyer Information

Order Summary